Haemonetics (NYSE:HAE) Issues FY 2026 Earnings Guidance

Key Points

• Haemonetics has issued FY 2026 earnings guidance with an expected EPS of 4.700-5.00, slightly below the consensus estimate of 4.866.
• The company's stock opened at $75.81 and has a market cap of $3.64 billion, indicating significant growth potential within the medical instruments sector.
• Current analyst sentiment includes a majority rating of "Moderate Buy", with a consensus price target of $97.30, suggesting optimism in future stock performance.

Haemonetics (NYSE:HAE - Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 4.700-5.00 for the period, compared to the consensus EPS estimate of 4.866. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on HAE. JPMorgan Chase & Co. reiterated a "neutral" rating and set a $62.00 price target (down from $85.00) on shares of Haemonetics in a research report on Friday. Baird R W upgraded Haemonetics to a "strong-buy" rating in a report on Wednesday, June 25th. Wall Street Zen lowered Haemonetics from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Mizuho dropped their price objective on Haemonetics from $90.00 to $70.00 and set an "outperform" rating on the stock in a research note on Friday. Finally, Robert W. Baird began coverage on Haemonetics in a research note on Thursday, June 26th. They issued an "outperform" rating and a $87.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $85.18.

Haemonetics Trading Down 2.6%

Shares of HAE stock traded down $1.42 on Monday, hitting $52.57. The stock had a trading volume of 507,732 shares, compared to its average volume of 781,596. Haemonetics has a twelve month low of $52.48 and a twelve month high of $94.99. The firm has a market cap of $2.53 billion, a P/E ratio of 16.07, a PEG ratio of 0.88 and a beta of 0.40. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04. The company has a fifty day moving average price of $72.88 and a two-hundred day moving average price of $67.36.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.09. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The company had revenue of $321.39 million during the quarter, compared to analyst estimates of $305.12 million. During the same quarter in the previous year, the business earned $1.02 EPS. The firm's revenue was down 4.4% on a year-over-year basis. As a group, analysts forecast that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

Several institutional investors and hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Haemonetics by 3.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier's stock worth $1,877,000 after purchasing an additional 971 shares during the period. Caxton Associates LLP acquired a new position in Haemonetics in the 1st quarter worth $216,000. United Services Automobile Association acquired a new position in Haemonetics in the 1st quarter worth $212,000. Empowered Funds LLC boosted its stake in Haemonetics by 9.1% in the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier's stock worth $283,000 after purchasing an additional 372 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Haemonetics by 6.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier's stock worth $9,923,000 after purchasing an additional 9,051 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.